1. Sachdeva MM, Stoffers DA. Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion. Mol Endocrinol 2009; 23: 747–758.
2. Hribal ML, Oriente F, Accili D. Mouse models of insulin resistance. Am J Physiol Endocrinol Metab 2002; 282: E977–E981.
3. Jetton TL, Liang Y, Cincotta AH. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta- cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. Metabolism 2001; 50: 1377–1384.
4. Peshavaria M, Larmie BL, Lausier J, et al. Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. Diabetes 2006; 55: 3289–3298.
5. Parsons JA, Brelje TC, Sorenson RL. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 1992; 130: 1459–1466.
6. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16: 804–808.
7. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 2011; 121: 2118–2125.
8. Bonner-Weir S, Deery D, Leahy JL, et al. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 1989; 38: 49–53.
9. Jetton TL, Everill B, Lausier J, et al. Enhanced beta-cell mass without increased proliferation following chronic mild glucose infusion. Am J Physiol Endocrinol Metab 2008; 294: E679–E687.
10. Stamateris RE, Sharma RB, Kong Y, et al. Glucose induces mouse b-cell proliferation via IRS2, MTOR, and Cyclin D2 but not the insulin receptor. Diabetes 2016; 65: 981–995.
11. Lipsett M, Finegood DT. Beta-cell neogenesis during prolonged hyperglycemia in rats. Diabetes 2002; 51: 1834–1841.
12. Maekawa R, Seino Y, Ogata H, et al. Chronic high-sucrose diet increases fibroblast growth factor 21 production and energy expenditure in mice. J Nutr Biochem 2017; 49: 71–79.
13. Niwa Y, Ishikawa K, Ishigami M, et al. Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. Biochem Biophys Res Commun 2015; 463: 344–350.
14. Maekawa R, Ogata H, Murase M, et al. Glucose-dependent insulinotropic polypeptide is required for moderate high fat diet, but not high carbohydrate diet-induced weight gain. Am J Physiol Endocrinol Metab 2018; 314: E572–E583.
15. Miki T, Nagashima K, Tashiro F, et al. Defective insulin secretion and enhanced insulin action in KATP channel- deficient mice. Proc Natl Acad Sci USA 1998; 95: 10402–10406.
16. Miki T, Minami K, Shinozaki H, et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056–1063.
17. Ogata H, Seino Y, Harada N, et al. KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol 2014; 222: 191–200.
18. Iwasaki M, Minami K, Shibasaki T, et al. Establishment of new clonal pancreatic b-cell lines (MIN6-K) useful for study of incretin/cyclic adenosine monophosphate signaling. J Diabetes Investig 2010; 1: 137–142.
19. Seino Y, Ogata H, Maekawa R, et al. Fructose induces glucose-dependent insulinotropic polypeptide, glucagon- like peptide-1 and insulin secretion: role of adenosine triphosphate-sensitive K(+) channels. J Diabetes Investig 2015; 6: 522–526.
20. Iida A, Seino Y, Fukami A, et al. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon- deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia 2016; 59: 1533–1541.
21. Fukami A, Seino Y, Ozaki N, et al. Ectopic expression of GIP in pancreatic b-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 2013; 62: 510–518.
22. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900–904.
23. Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest 2004; 114: 963–968.
24. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246–257.
25. Hennige AM, Burks DJ, Ozcan U, et al. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 2003; 112: 1521–1532.
26. Georgia S, Hinault C, Kawamori D, et al. Cyclin D2 is essential for the compensatory beta-cell hyperplastic response to insulin resistance in rodents. Diabetes 2010; 59: 987–996.
27. Alonso LC, Yokoe T, Zhang P, et al. Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes 2007; 56: 1792–1801.
28. Salpeter SJ, Klochendler A, Weinberg-Corem N, et al. Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic b-cells through glycolysis and calcium channels. Endocrinology 2011; 152: 2589–2598.
29. Moull´e VS, Vivot K, Tremblay C, et al. Glucose and fatty acids synergistically and reversibly promote beta cell proliferation in rats. Diabetologia 2017; 60: 879–888.
30. Pascoe J, Hollern D, Stamateris R, et al. Free fatty acids block glucose-induced b-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 2012; 61: 632–641.
31. Stamateris RE, Sharma RB, Hollern DA, et al. Adaptive b-cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression. Am J Physiol Endocrinol Metab 2013; 305: E149–E159.
32. Tajima K, Shirakawa J, Okuyama T, et al. Effects of metformin on compensatory pancreatic b-cell hyperplasia in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2017; 313: E367–E380.
33. Levitt HE, Cyphert TJ, Pascoe JL, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia 2011; 54: 572–582.
34. Metukuri MR, Zhang P, Basantani MK, et al. ChREBP mediates glucose-stimulated pancreatic b-cell proliferation. Diabetes 2012; 61: 2004–2015.
35. Lingohr MK, Briaud I, Dickson LM, et al. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 2006; 281: 15884–15892.
36. Demozay D, Tsunekawa S, Briaud I, et al. Specific glucose- induced control of insulin receptor substrate-2 expression is mediated via Ca2+-dependent calcineurin/NFAT signaling in primary pancreatic islet b-cells. Diabetes 2011; 60: 2892–2902.
37. Shirakawa J, Togashi Y, Sakamoto E, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic b-cells. Diabetes 2013; 62: 3448–3458.
38. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443: 345–349.
39. Srinivasan S, Bernal-Mizrachi E, Ohsugi M, et al. Glucose promotes pancreatic islet beta-cell survival through a PI 3- kinase/Akt-signaling pathway. Am J Physiol Endocrinol Metab 2002; 283: E784–E793.
40. Wang W, Walker JR, Wang X, et al. Identification of small- molecule inducers of pancreatic beta-cell expansion. Proc Natl Acad Sci USA 2009; 106: 1427–1432.
41. Porat S, Weinberg-Corem N, Tornovsky-Babaey S, et al. Control of pancreatic b cell regeneration by glucose metabolism. Cell Metab 2011; 13: 440–449.
42. Nakamura A, Togashi Y, Orime K, et al. Control of beta cell function and proliferation in mice stimulated by small- molecule glucokinase activator under various conditions. Diabetologia 2012; 55: 1745–1754.
43. Guiot Y, Henquin JC, Rahier J. Effects of glibenclamide on pancreatic beta-cell proliferation in vivo. Eur J Pharmacol 1994; 261: 157–161.
44. Namkung Y, Skrypnyk N, Jeong MJ, et al. Requirement for the L-type Ca(2 + ) channel alpha(1D) subunit in postnatal pancreatic beta cell generation. J Clin Invest 2001; 108: 1015–1022.
45. Futamura M, Yao J, Li X, et al. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 2012; 55: 1071–1080.
46. Wei P, Shi M, Barnum S, et al. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. Diabetologia 2009; 52: 2142–2150.
47. Kassem S, Bhandari S, Rodr´ıguez-Bada P, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med 2010; 362: 1348–1350.
48. Cuesta-Mun~oz AL, Huopio H, Otonkoski T, et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004; 53: 2164–2168.
49. Kulkarni RN, Bru€ning JC, Winnay JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329–339.
50. Otani K, Kulkarni RN, Baldwin AC, et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab 2004; 286: E41–E49.
51. Ueki K, Okada T, Hu J, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 2006; 38: 583–588.
52. Okada T, Liew CW, Hu J, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci USA 2007; 104: 8977–8982.
53. Hashimoto N, Kido Y, Uchida T, et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006; 38: 589–593.
54. Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 2001; 7: 1133–1137.
55. Bernal-Mizrachi E, Wen W, Stahlhut S, et al. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 2001; 108: 1631–1638.
56. Seino Y, Miki T, Fujimoto W, et al. Cephalic phase insulin secretion is KATP channel independent. J Endocrinol 2013; 218: 25–33.